Adrienne L Graves bought HROW once, on May 18, 2026

Adrienne L. Graves, Ph.D., is an independent director and corporate insider at Harrow, Inc. (Nasdaq: HROW), having joined the company’s board of directors in January 2024 and recently purchasing 1,000 shares of Harrow common stock in an open-market transaction reported on May 18, 2026.( A visual scientist by training and global leader in ophthalmology, she previously served as President and Chief Executive Officer of Santen Inc., the U.S. subsidiary of a major Japanese ophthalmic pharmaceutical company, from 2002 to 2010, after seven years as Senior Vice President of Worldwide Clinical Development overseeing the U.S., Europe, and Japan.(

Dr. Graves has extensive board experience across biopharmaceutical and ophthalmology-focused companies and foundations. She has served on the boards of Ocular Therapeutix, Nicox, Surface Ophthalmics, Opus Genetics, Qlaris Bio, NVasc, JelliSee, Implandata, and others, and previously chaired the board of IVERIC bio until its 2023 acquisition by Astellas.( Earlier in her career, she spent nine years at Alcon, where she built a retinal electrophysiology lab and held leadership roles in clinical development and international ophthalmology.( She earned an A.B. with honors in psychology from Brown University, a Ph.D. in psychobiology/neuroscience from the University of Michigan, and completed a postdoctoral fellowship in visual neuroscience at the University of Paris.(

Written by Perplexity from public sources.